Physician profile
Maribeth Evans
NPI 1003476888
$3,369.73
in general payments reported to CMS, 2019-2025
12 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2022: $382 · 2023: $536 · 2024: $1,310 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.63 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,051.23 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $501.30 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $468.86 | 2022-2025 | Invega Sustenna, Invega, Invega Trinza |
| Alkermes, INC. | $447.78 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $310.36 | 2022-2025 | |
| Braeburn INC. | $265.02 | 2023-2025 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $127.39 | 2023-2025 | Uzedy |
| Axsome Therapeutics, INC. | $97.54 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $46.33 | 2024 | Ingrezza |
| Janssen Biotech, INC. | $23.31 | 2023 | Tecvayli, Darzalex |
| Corium, LLC | $16.68 | 2025 | Azstarys |
| Luye Pharma (USA) LTD. | $13.93 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maribeth Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.